There is a long waiting list for human patients in need of healthy organs. Soon, organ replacement may be as simple as bioprinting the required body tissue. Read More

As AT&T grapples with the multi-media revolution, can this legacy telecom light a fire under its lagging stock price? Read More

In our weekly interview with a top Investing Daily analyst, we discuss a wide range of topical issues of crucial importance to investors. Read More

Visa is the largest credit card payment outfit in the U.S. Will the stock continue its winning streak this year or will tech "disruptors" knock the company off its perch? Read More

Demand for hybrid cloud storage will continue to grow as more users optimize the cost of managing their data. Will NetApp stock benefit as a result? Read More

Exxon Mobil stock is highly leveraged to the price of oil. So, if oil prices recover in 2019, XOM's share price should should spike higher. Read More

Rho is a gauge that helps you evaluate options contracts and their exposure to the risk of interest rate fluctuations. Here's how it works. Read More

We frequently advise investors to know their risk tolerance. Here's a time-tested measure for understanding the potential volatility in your portfolio. Read More

The rising incidence of hacking dominates the front pages. We examine cybersecurity firm Bravatek to see if it's a growth play or just another risky fad stock. Read More

Nike is one of the most recognizable brands in the world. The company has faced some stiff competition lately. Will it remain Number One? Read More

This global colossus dominates the thriving management consulting industry. But as the pace of change accelerates, can the company stay on top? Read More

There's a trio of economic trends that will drive the market higher this year. Shareholders of these three companies stand to benefit the most. Read More

An examination of Therapix Biosciences, its rivals, and a prediction for this micro-cap biotech stock in 2019. Will Therapix prove a winner or loser in the race to develop cannabis-based drugs? Read More

An examination of Supreme Cannabis stock, its rivals, whether it's overpriced or underpriced, and a prediction for the stock in 2019. Read More

Amazon's new headquarters near Washington DC could elevate Jeff Bezos’ legacy to something far greater than being remembered as the guy that wrecked retail. Read More

Our review of clinical-stage medical cannabis companies continues, with a fledgling biotech that's generating especially keen interest on Wall Street. Is Cara a future bonanza... or short-term fad? Read More